Prosigna identified a large high-clinical-risk subgroup with minimal chemotherapy benefit, estimated to avert at most two recurrences per 100 patients treated. Enrollment broadened prior assay use by ...
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ...
Breast cancer is the second leading cause of cancer death among women, according to the American Cancer Society. Now, three recent studies by researchers at Sylvester Comprehensive Cancer Center, part ...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective ...
Most breast cancer patients in Uganda and Ethiopia are diagnosed too late, and many lack access to life-saving treatment. Tove Ekdahl Hjelm defends her thesis "Early-onset breast cancer in East Africa ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results